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J. M. C. Yeung, M. Heeley, S. Gray, M. K. Lingam, G. Manning, J. R. Nash and R. Donnelly
School of Medical & Surgical Sciences, University of Nottingham, and
Southern Derbyshire Acute Hospitals Trust, Derby, U.K.
Objectives: the tissue renin-angiotensin system (RAS), which plays an important role in vascular structure and function,
is regulated in part by an insertion-deletion polymorphism of the angiotensin converting enzyme (ACE) gene. We
hypothesised that ACE genotype might affect rate of AAA expansion via modulating long-term structural changes
associated with RAS activation.
Methods: fifty-eight patients (50 M, mean age 70 years, mean initial aneurysm size 4.3 cm) with current or previous AAA
and serial (43) annual ultrasound measurements of antero-posterior AAA size provided a sample of leucocyte DNA for
ACE genotyping. AAA expansion rate (cm per year) for individual subjects was calculated by linear regression.
Results: median AAA expansion rate was 0.28 cm/year (range 0±1.8 cm/year), and the genotype distribution included DD
(n 14), DI (n 29) and II (n 15). Corresponding median AAA expansion rates for each of the three genetic subgroups
were 0.22, 0.32 and 0.30 cm/year, respectively (p 0.6, nonparametric).
Conclusions: the wide inter-individual variability in AAA expansion rate is likely to reflect complex genetic and
environmental interactions, but the lack of any relationship with ACE genotype suggests that differences in vascular
ACE activity in aortic tissue are not major determinants of the variability in rate of AAA dilatation.
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It is likely that genetic and environmental factors con-
tribute to the aetiology and progression of abdominal
aortic aneurysm (AAA),1 but the mechanisms regu-
lating arterial elasticity, inflammatory mediators and
vessel dilatation in AAA remain unclear. Components
of the renin-angiotensin system (RAS) are heavily
expressed within vascular tissues, and up-regulation
of local angiotensin II (ANG II) formation is associated
with adverse autocrine effects on arterial structure
and function, e.g. tissue RAS activity is a major deter-
minant of vascular tone.2 ANG II accelerates the pro-
gression of atherosclerosis, and in experimental mice
administration of exogenous ANG II induces the
formation and expansion of AAA,3 possibly via up-
regulation of urokinase-type plasminogen activator.4
Furthermore, blockade of ANG II formation by ACE
inhibitors reduces aneurysm expansion rate in the
elastase-induced AAA model in rats.5Please address all correspondence to: R. Donnelly, Division of
Vascular Medicine, University of Nottingham, Derbyshire Royal
Infirmary, Derby DE1 2QY, U.K.
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identified in which the absence (deletion, D-allele)
rather than the presence (insertion, I-allele) of a
287 bp fragment is associated with increased ACE
activity in tissues.6,7 A meta-analysis has confirmed
that individuals with the DD genotype have a higher
incidence of major cardiovascular events,8 but pre-
vious studies exploring the role of the ACE genotype
in the aetiology of AAA have been inconsistent.9,10
The D-allele, however, also affects pathways involved
in structural remodelling, e.g. calcification11 and
dilatation,12 which led us to hypothesise that ACE
genotype (as a regulator of aortic RAS activity) might
be more important in determining the rate of dilata-
tion (as opposed to the incidence) of AAA.
Materials and Methods
Patients with current or previous AAA and at least
three serial (usually annual) ultrasound measure-
ments of antero-posterior AAA size were recruited
from the aneurysm surveillance database at therights reserved.
70 J. M. C. Yeung et al.Derbyshire Royal Infirmary (the vascular unit serves a
population of 560 000). All AAA size measurements in
the Vascular Unit are performed by two experienced
technicians with inter-observer variability 56%. Clin-
ical and demographic details were collected, includ-
ing rate of AAA progression (cm per year), and a
blood sample was obtained for leucocyte DNA. The
protocol was approved by the Southern Derbyshire
Research Ethics committee.
ACE genotype
Genomic DNA from individual subjects was ampli-
fied by PCR using the primer sequences and PCR
conditions described previously.13 The PCR product(s)
were resolved on a 2% agarose gel, stained with ethi-
dium bromide, and individual subjects were classified
into one of 3 genotypes according to the presence or
absence of a 287 bp fragment: Deletion/Deletion (DD),
Deletion/Insertion (DI), and Insertion/Insertion (II).
Statistical analysis
AAA expansion rate for individual subjects was
derived from the slope of a linear regression analysis
of serial ultrasound measurements (mean observation
period 28 months). Expansion rates were not normally
distributed, therefore data are presented as the median
and interquartile ranges (25 and 75%). Differences in
expansion rate between the three genotype groups
were analysed by nonparametric analysis of variance
(Kruskal±Wallis test). Initial AAA sizes, however,
were normally distributed among the 58 subjects.
Stepwise multiple regression analysis was used to
relate the odds of each outcome, e.g. rate of AAA
progression, to the ACE genotype and clinicalTable 1. Clinical and demographic features for e
ACE g
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(n 14
Age (years) 717
AAA expansion rate (cm/year)
(median and interquartile ranges)
0.22
(0.12, 0
BMI (kg/m2) 25.52
BP (mmHg) 141/77
Total cholesterol (mM) 5.41.
ACE inhibitor use (%) 4 (29)
MeanSD, except for AAA expansion rate (medi 25% and 75% interquartile ranges.
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size, are presented as meanstandard deviation.
Results
Fifty-eight patients (50 M, mean age 70 years) with a
mean aneurysm size at diagnosis of 4.3 cm and aver-
age AAA expansion rate of 0.35 cm/year participated
in the study. All except one subject had an initial
AAA size 43.0 cm. The genotype distribution was
as follows: 14 patients (24%) were DD, 29 (50%) were
DI, and 15 (26%) were II, which is consistent with
Hardy±Weinberg equilibrium. Initial aneurysm sizes
(mean+SD) were similar in the 3 genotype groups:
4.0+0.8 (DD), 4.3+0.8 (DI), and 4.4+0.6 cm (II)
(one-way ANOVA, p 0.32). There were no significant
differences in the rate of AAA expansion between the
three genetic subgroups (Table 1) (p 0.6, Kruskal±
Wallis test).
Discussion
Activation of the tissue-based RAS in the blood vessel
wall plays an important role in the pathogenesis of
structural and functional abnormalities associated
with various cardiovascular disorders, e.g. athero-
sclerosis, heart failure and the microvascular compli-
cations of diabetes.14,15 There is evidence that ACE
genotype affects circulating and tissue ACE enzymatic
activity,6,7 and therefore the ACE polymorphism
may account for clinical differences in the long-term
progression of renal, cardiac and vascular abnormal-
ities mediated by the RAS and local ANG II formation.
The importance of this pathway is further supported
by therapeutic trials showing that ACE inhibitors
have favourable effects on vascular structure,
including effects on aortic compliance, distensibility
and AAA size.5,16ach ACE genotype group.
enotype
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ACE Genotype and AAA Expansion 71This is the first clinical study to investigate ACE
genotype in relation to AAA expansion rate. As in
other clinical series, there were wide inter-individual
differences in rate of AAA expansion which could not
be explained by simple clinical parameters such as
age, BP or serum lipids. The measurements of AAA
progression were derived for individual subjects
using linear regression based on serial (usually
annual) ultrasound recordings made over an average
follow-up period of 28 months. The average rates
of AAA growth (0.17±0.57 cm/year) were broadly
similar to previously published reports.17 Half of the
study participants were heterozygote for the insertion-
deletion polymorphism, but the rate of AAA progres-
sion was very similar in each of the three genetic
subgroups. While it is difficult to fully exclude the pos-
sibility of a type II error because of the small sample
size, the n-values in each group and the comparability
in other clinical parameters (Table 1) strongly suggest
that ACE genotype has no predictive utility for iden-
tifying patients with AAA in whom rapid dilatation
and early surgical intervention is more likely.
These data tend to suggest that the tissue ACE
activity within the aortic wall is of relatively little
importance in determining the rate of AAA dilatation.
Specifically, there was no evidence that the D-allele
(associated with higher ACE activity) conferred a
harmful or protective effect in AAA outcome, e.g. via
ANG II induced smooth muscle hyperplasia strength-
ening the aortic wall. This does not, however, exclude
other components of the RAS playing a role in AAA
progression, e.g. differences in expression and affinity
of the AT1-receptor.
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